title: Radioactive synovectomy with (90) yttrium and (153) samarium hydroxyapatite in haemophilic joints: preliminary study on radiation safety.
abstract: Most countries still do not achieve 1 IU of factor VIII/capita sufficient for survival. Although primary prophylaxis prevents synovitis, is not universally used. Chronic synovitis is treated with arthroscopy at expense of considerable amount of coagulation factors, and specialized surgeons. Radioactive synovectomy (RS) is a minimally invasive and cost effective alternative to arthroscopy, often considered first the option for persistent synovitis. Even without established causation with cancer, RS is avoided by some, due to this concern. We aim contributing to the understanding of RS safety regarding malignancy, presenting a large number of treated patients, and a single case of cancer. Three centres in Brazil applied RS with (90) Yttrium Citrate, (90) Yttrium hydroxyapatite or (153) Samarium hydroxyapatite in haemophilic joints and performed a survey addressing cancer in these patients. Four hundred and eighty eight patients (ages 3-51) received 1-3 RS (total 842) and follow-up was 6 months to 9 years. One patient aged 14 years presented Ewing sarcoma, 11 months after RS. The tumour was treated successfully with surgery and chemotherapy. Causality of cancer by RS is improbable in this case. Accordingly, latency here is far below minimum 5-10 years for radio-induction of solid tumours. Moreover, ES is not a typically radio-induced tumour, even at high doses. In agreement with others, though recognizing limitations, this study suggests RS is safe regarding cancer induction. Synovitis is a known burden for patients. The decision of making reasonable usage of RS should be outweighed with the risks of leaving synovitis untreated.
authors.affiliation: Ambulatorio de Hematologia, Hemomat, Cuiaba, Brazil. sylviahemato@gmail.com
authors.forename: S
authors.initials: S
authors.lastname: Thomas
authors.forename: J D
authors.initials: JD
authors.lastname: Mendes
authors.forename: S A
authors.initials: SA
authors.lastname: Souza
authors.forename: C S
authors.initials: CS
authors.lastname: Lorenzato
authors.forename: P E
authors.initials: PE
authors.lastname: Assi
authors.forename: L R L
authors.initials: LR
authors.lastname: Pacheco
authors.forename: M B
authors.initials: MB
authors.lastname: Gabriel
authors.forename: A
authors.initials: A
authors.lastname: Bordim
authors.forename: B
authors.initials: B
authors.lastname: Gutfilen
authors.forename: L M B
authors.initials: LM
authors.lastname: da Fonseca
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006306:Health Surveys; D006467:Hemophilia A / Q000000981:diagnostic imaging*; D006801:Humans; D006882:Hydroxyapatites / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D007596:Joints / Q000000981:diagnostic imaging* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced; D011877:Radionuclide Imaging; D012493:Samarium / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D013583:Synovial Membrane / Q000000981:diagnostic imaging*; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000009:adverse effects
chemical_list: D006882:Hydroxyapatites; D015021:Yttrium Radioisotopes; C091049:samarium hydroxyapatite; D012493:Samarium